Skip to main content

Table 8 Comparative susceptibility profile of S. aureus species to different concentrations of honey

From: Antimicrobial analysis of honey against Staphylococcus aureus isolates from wound, ADMET properties of its bioactive compounds and in-silico evaluation against dihydropteroate synthase

Susceptibility to different concentrations of honey

 

Neat (100%)

1:2 (50%)

1:4 (25%)

1:8 (12.5%)

1:16 (6.25%)

1:32 (3.13%)

1:64 (1.57%)

1:128 (0.79%)

1:256 (0.40%)

Test organisms (n = 47)

S

R

S

R

S

R

S

R

S

R

S

R

S

R

S

R

S

R

Patient 1 (20)

20

(100.0)

0

(0.0)

18

(90.0)

2

(10.0)

17

(85.0)

3

(15.0)

16

(80.0)

4

(20.0)

15

(75.0)

5

(25.0)

13

(65.0)

7

(35.0)

9

(45.0)

11

(55.0)

6

(30.0)

14

(70.0)

3

(15.0)

17

(85.0)

Patient 2 (6)

6

(100.0)

0

(0.0)

6

(100.0)

0

(0.0)

4

(67.0)

2

(33.0)

4

(67.0)

2

(33.0)

3

(50.0)

3

(50.0)

2

(33.0)

4

(67.0)

1

(16.7)

5

(83.3)

0

(0.0)

6

(100.0)

0

(0.0)

6

(100.0)

Patient 3(7)

7

(100.0)

0

(0.0)

6

(85.7)

1

(14.3)

6

(85.7)

1

(14.3)

5

(71.4)

2

(28.6)

4

(57.1)

3

(42.9)

3

(42.9)

4

(57.1)

2

(28.6)

5

(71.4)

1

(14.3)

6

(85.7 l)

0

(0.0)

7

(100.0)

Patient 4(5)

5

(100.0)

0

(0.0)

4

(80.0)

1

(0.0)

4

(80.0)

1

(20.0)

3

(60.0)

2

(40.0)

2

(40.0)

3

(60.0)

1

(20.0)

4

(80.0)

0

(0.0)

5

(100.0)

0

(0.0)

5

(100.0)

0

(0.0)

5

(100.0)

Patient 5(2)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

1

(50.0)

1

(50.0)

1

(50.0)

1

(50.0)

0

(0.0)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

2

(100.0)

Patient 6(7)

6

(100.0)

0

(0.0)

6

(85.7)

1

(14.3)

5

(71.4)

2

(28.6)

3

(42.9)

4

(57.1)

2

(28.6)

5

(71.4)

2

(28.6)

5

(71.4)

1

(14.3)

6

(85.7)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

Susceptibility to different concentrations of trimethoprim

 

0.39 mg/ml

078 mg/ml

1.56 mg/ml

3.13 mg/ml

6.25 mg/ml

12.50 mg/ml

25.0 mg/ml

50.0 mg/ml

100 mg/ml

Test organisms (n = 47)

S

R

S

R

S

R

S

R

S

R

S

R

S

R

S

R

S

R

Patient 1 (20)

0

(0.0)

20

(100.0)

2

(10.0)

18

(90.0)

5

(25.0)

15

(75.0)

9

(45.0)

11

(55.0)

14

(70.0)

6

(30.0)

17

(85.0)

3

(15.0)

18

(90.0)

2

(10.0)

20

(100.0)

0

(0.0)

20

(100.0)

0

(0.0)

Patient 2 (6)

0

(0.0)

6

(100.0)

0

(0.0)

6

(100.0)

1

(16.7)

5

(83.3)

2

(33.3)

4

(66.7)

4

(66.67)

2

(33.3)

6

(100.0)

0

(0.0)

6

(100.0)

0

(0.0)

6

(100.0)

0

(0.0)

6

(100.0)

0

(0.0)

Patient 3 (7)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

2

(28.6)

5

(71.4)

3

(42.9)

4

(57.1)

3

(42.9)

4

(57.1)

7

(100.0)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

0

(0.0)

Patient 4 (5)

0

(0.0)

5

(100.0)

0

(0.0)

5

(100.0)

1

(20.0)

4

(80.0)

2

(40.0)

3

(60.0)

4

(80.0)

1

(20.0)

5

(100.0)

0

(0.0)

5

(100.0)

0

(0.0)

5

(100.0)

0

(0.0)

5

(100.0)

0

(0.0)

Patient 5 (2)

0

(0.0)

2

(50.0)

0

(0.0)

2

(50.0)

0

(0.0)

2

(100.0)

1

(50.0)

1

(50.0)

0

(0.0)

2

(50.0)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

2

(100.0)

0

(0.0)

Patient 6 (7)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

2

(28.6)

5

(71.4)

3

(42.9)

4

(57.1)

4

(57.1)

3

(42.9)

7

(100.0)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

0

(0.0)

7

(100.0)

0

(0.0)

Back to article page

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us